Three biotechs re­veal some se­crets about them­selves as they gun for $271M-plus in IPOs

Last week end­ed with an­oth­er Fri­day night blitz of biotech S-1s as a fresh wave of new of­fer­ings forms to crash in­to Nas­daq. En­ter­ing the Wall Street spot­light now is one transat­lantic op­er­a­tion that is out to de­vel­op a new class of meds, a Dal­las biotech with a Phase III kid­ney can­cer drug and a start­up that in-li­censed its lead drug from No­var­tis.

They are all on­col­o­gy fo­cused, high­light­ing the big mon­ey that con­tin­ues to pour in­to all things can­cer re­lat­ed.

Each of these 3 biotechs has been par­tial to the clas­sic biotech start­up game plan, where you flag in­com­ing col­lab­o­ra­tions with the biggest names you can find to work with — while of­ten stay­ing mum about the cash in­volved and/or keep­ing the de­tails about their lead pro­grams un­der wraps.

On­col­o­gy, af­ter all, is an in­tense­ly com­pet­i­tive field. But come the S-1s, se­crets must be spilled.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER